This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
Sanofi and Regeneron’s Dupixent is currently on track to receive approval for uncontrolled CSU this year. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of the interleukin-4 and interleukin-13 pathways, shown in the
Sanofi and Regeneron’s Dupixent (dupilumab) was approved by the FDA in September last year as the first and only treatment indicated for prurigo nodularis.
The positive results for amlitelimab come just a few months after Sanofi and Regeneron’s Dupixent (dupilumab) was approved by the European Commission to treat severe atopic dermatitis in children aged ... The approval made Dupixent the first targeted
The study also showed a 160ml improvement in lung function from baseline at 12 weeks in the Dupixent-treated cohort versus 77ml in the control group. ... Dupixent has already received regulatory approvals for use in certain patients with atopic dermatitis
Sanofi and Regeneron’s Dupixent (dupilumab) was associated with significant improvements in uncontrolled prurigo nodularis symptoms, according to positive phase 3 results recently published in Nature Medicine. ... Dupixent is already approved to treat
The announcement comes just days after Regeneron and partner Sanofi’s Dupixent (dupilumab) was approved by the European Commission to treat severe atopic dermatitis in children aged six months to five ... The approval, which follows a positive opinion
More from news
Approximately 39 fully matching, plus 38 partially matching documents found.
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...